Advancing Aortic Technologies with Purpose™



A new, innovative, life-changing purpose is driving aortic-centric technologies.

ARTIVION®

We will serve each and every patient with aortic disease through **collaboration** with cardiac and vascular surgeons to deliver the best solutions. Our **intention** and **focused commitment** to advancing the treatment of aortic diseases are fueled by the **precision** of our engineering excellence and aortic expertise.

Our purpose is to develop simple, elegant solutions that address surgeons' most difficult challenges in treating patients with diseases of the aorta and to deliver breakthrough technologies of unsurpassed quality that have far-reaching impact.

We are Artivion.

NYSE: AORT

An Aortic-Driven Journey

Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions worthy of their commitment and experience in treating and impacting the lives of patients with diseases of the aorta.

1984
CryoLife® founded as an allograft tissue storage and shipping service

1991
SynerGraft® technology developed

1996
Technology acquisition: **BioGlue®**

2015
Total addressable market
$600M

2016
Company acquisition: **On-X® Life Technologies**

2016
Divestiture: **HeRO**

2016
Divestiture: **ProCol**

2017
Company acquisition: **Jotec®**

2019
Portfolio expansion: **NEXUS® by Endospan®**

2020
Company acquisition: **Ascyrus Medical®**

2020
Total addressable market
$6B

2021
Divestiture: **PerClot®**

2022
Corporate rebrand: **Artivion™**

Leading the Advancement of Treating Aortic Diseases

Every day, our 1,250+ global employees dedicate themselves to delivering on the Artivion mission, vision, and established core values—working together to form the foundation of an innovative, productive, and sustainable culture.

Our Mission

We partner with surgeons to restore the health of patients by delivering innovative technologies of unsurpassed quality.

Our Vision

To be recognized as a leader in providing technologies for patients with aortic disease.

We are Guided by These Three Key Principles and Fundamental Beliefs:

Collaboration

Working together to deliver for our customers, shareholders, and each other. As we work collaboratively, we're always truthful and transparent and stand up for what's right.

Results Driven

Getting it done. Being accountable. Focusing on solutions. Leaning in and bringing out the best in others, and always executing with integrity.

Customer Focused

Serving all our customers, externally and internally, with exceptional performance. We dedicate ourselves to treating everyone with respect.

When the need is aortic, the solution is Artivion.

Our intentional focus on the aorta and collaboration with the world's foremost cardiac and vascular surgeons allow us to leverage our combined expertise in the development of new, innovative, life-changing aortic-centric technologies.



Surgical Sealant

BioGlue®

Surgical Sealant

Aortic Heart Valves

On-X®

Mechanical Valves

CryoValve®

Aortic Allograft

CryoValve® SG



Pulmonary Allograft

Aortic Arch Solutions*

AMDS™

Surgical Acute Type A Dissection

E-vita® Open Neo

Arch Aneurysm & Chronic Dissection

NEXUS®

Endovascular Branched Arch

Abdominal Aortic Solutions*

E-nside™ TAAA

Thoracoabdominal

E-tegra™

Abdominal

E-liac™

Iliac

* Products are not currently available in the US.

Future-Defining Aortic Innovations

Our commitment to bringing breakthrough technologies of unsurpassed quality drives everything we do—today and well into the future. Here are the future-defining solutions in our aortic-centric portfolio:

A Valve for Life

On-X
Aortic Valve

The On-X Aortic Heart Valve is the only mechanical aortic heart valve approved by the FDA and supported by the ACC/AHA guidelines for management at a low dose INR of 1.5 to 2.0 (following 3 months of standard therapy).[1,2] It is also the only aortic valve currently enrolling in the PROACT Xa clinical trial[3] to determine if patients can be safely maintained on Apixaban.

Groundbreaking Innovation in Management of Thoraco-abdominal Aneurysms (TAAA)

E-nside TAAA
Multibranch Stent Graft System

We aim to make the revolutionary, routine with the E-nside TAAA Multibranch Stent Graft System—the first pre-cannulated, inner branch based, off-the-shelf solution for TAAA. This device is CE marked with approved indications for thoracoabdominal aneurysms[4] and has been designated as a "Breakthrough Device" by the FDA.

*Note: All products and indications are not available/approved in all markets. Please contact your local Artivion representative for details.

*The NEXUS Endovascular device is manufactured by Endospan Ltd. and distributed by Artivion.

Unique and Comprehensive Aortic Arch Solutions

AMDS
Hybrid Prosthesis

When used adjunctive to standard hemiarch repair in Acute Type A Aortic Dissection, the AMDS hybrid prosthesis elevates the standard of care while sealing distal anastomotic new entry (DANE) and facilitating 100% arch remodeling.[5] This device is CE marked[6] and has been designated as a "Breakthrough Device" by the FDA. The PERSEVERE Pivotal IDE Study will begin enrollment in the US in 2022.

NEXUS
Endovascular Branched Arch

The NEXUS device offers an endovascular approach to total arch repair when open repair can be risky. It is CE marked with approved indications for chronic dissections and aneurysms.[7] The NEXUS Endovascular Branched Arch system has been designated as a "Breakthrough Device" by the FDA and is currently enrolling in the TRIOMPHE Study in the US.[8]



E-vita Open Neo
Hybrid Stent Graft System

We were first to market with a Frozen Elephant Trunk hybrid system. This next generation total arch repair system offers multiple designs for patient-specific head vessel management.[9, 10] This device is CE marked with approved indications for acute and chronic dissections and aneurysms,[9] and it has been designated as a "Breakthrough Device" by the FDA.

References:
1. On-X Prosthetic Heart Valve Instructions for Use
2. Otto CM, et al. Circulation. 2021;143:e72–e227
3. https://clinicaltrials.gov/ct2/show/NCT00291525
4. E-nside TAAA Instructions for Use
5. Bozso SJ, et al. Annals of Thoracic Surgery. 2021; 111.2: 463-70
6. AMDS Ascyrus Medical Dissection Stent Hybrid Prosthesis Instructions for Use
7. NEXUS by Endospan Instructions for Use
8. https://clinicaltrials.gov/ct2/show/NCT04471909
9. E-vita OPEN NEO Instructions for Use
10. Shrestha M, et al., European Journal of Cardio-Thoracic Surgery, 2013: 43.2: 406-10

Advancing with Purpose

Founded in 1984, we've grown into a multi-national organization of over 1,250 employees with sales representation and product manufacturing across the globe.

OUR GLOBAL PRESENCE

We've expanded our footprint—and impact—all over the world.



63 Sales Associates in North America

Austin, TX
USA Manufacturing

Kennesaw, GA
Headquarters
USA Manufacturing

88 Sales Associates in EMEA

Hechigen, Germany
EU Manufacturing

25 Sales Associates in APAC
50+ by end of 2024

10 Sales Associates in LATAM
14+ by end of 2024

Sales % by Geography*

57% North America

33% Europe, Middle East, and Africa (EMEA)

7% Asia Pacific (APAC)

3% Latin America (LATAM)

Employees Worldwide 1250+

Number of countries where our products are available 100+

NYSE SYMBOL AORT

*Percentages based on FY 2020 revenues.

Product Innovation and Global Expansion-Driven Growth Strategy

We're poised to deliver double-digit growth in 2022 and beyond based on the following key growth drivers:



Sales Mix by Product Groups*

29% Allograft Preservation Services

25% Surgical Sealants

24% Aortic Stent Grafts

19% Prosthetic Heart Valves

Revenue invested in research & development in 2021 **12%**

Total number of clinical trials globally **25+**

*Percentages based on FY 2020 revenues. Remaining 3% of 2020 revenues includes PerClot, TMR, and PhotoFix product revenues.

Support That Makes a Difference

We offer programs and services that sharpen the surgical expertise of cardiac and vascular surgeons and support access to products for treating patients with aortic disease.

Elite Education Experience

We are recognized as a leader in the mentorship and training of cardiac and vascular surgeons around the world. For over 20 years, we have provided training through various educational summits, physician training events, physician mentorship, and institutional wet lab support.

> Over 1,000 cardiac and vascular surgeons, fellows and residents globally attend our physician education programs every year.

E-xtra Design Engineering

With our E-xtra Design MultiBranch Stent Graft System, we offer the option of having individual configurations that are tailor-made for the patient's anatomy in the thoracoabdominal aorta. We have dedicated teams to help with planning, sizing, and implantation, so we can deliver your custom solution within 3 weeks of your request.*

> Over 5,000 successful implantations since the start of the program in 2012.

*Note: This service is not available in the US. Delivery times vary by geography.

Outreach Programs

We believe in supporting our clinicians through product donations and fundraising, so they can give back to the global community by operating on patients with limited access to treatment for aortic diseases.

> Partnered with 30+ different charitable organizations for 70+ different philanthropic events globally.
>
> Supported medical mission trips to 25+ different countries.
>
> Donated 500+ cardiac allografts, On-X valves, and other cardiovascular devices.
>
> Raised and donated over $70,000 each to Aswan Heart Center in Egypt and Boston Children's medical mission trip to Ghana.

Patient-Powered Progress

We provide solutions that have far-reaching impact on surgical outcomes and restoring the lives of patients fighting aortic diseases. Cardiac and vascular surgeons the world over—along with each patient in their care—have greatly benefited from our life-changing technologies.

> **“The main reason I decided to go with the On-X valve versus a tissue valve was I did not want to go through a third surgery.”**

Fred Hoiberg
On-X Aortic Heart Valve Recipient

> **“I never thought I would be able to do all the things I can do now after having a Ross Procedure; it was absolutely life-changing, life-transforming.”**

Donna Pierce
CryoValve SynerGraft Pulmonary Allograft Recipient for the Ross Procedure

> **“I really have to thank God for giving me a new opportunity, I don’t want to die as I need to keep taking care of my son.”**

Rosa
E-nside TAAA Recipient

Let’s Advance the Future Together

Artivion is dedicated to partnering with you to put the power of our end-to-end, aortic-centric product portfolio to work in treating and impacting the life of every patient with aortic disease.

We recognize that this is a fully collaborative effort. It demands a common mindset that connects us on the same path: driving progress and achieving breakthroughs that will fuel the next generation of simple, elegant, life-changing solutions.

Together, we’ll move beyond yesterday’s challenges as we work to reimagine the future possibilities in treating aortic disease.

Join us on this journey as we continue Advancing Aortic Technologies with Purpose.

Pat Mackin
Chairman, President & CEO

Artivion, Inc.

When the need is aortic, the solution is Artivion.

Our unrivaled, aortic-centric, end-to-end product portfolio:

Heart Valve Solutions

On-X® Aortic Heart Valve
On-X® Mitral Heart Valve
On-X® Ascending Aortic Prosthesis
Chord-X® Mitral Chordal Replacement Products
CryoValve® **SG** Pulmonary Human Heart Valve
CryoValve® Aortic Allograft

Allograft Solutions (Cardiac & Vascular)

CryoValve® Aortic Allograft
CryoValve® **SG** Pulmonary Human Heart Valve
CryoPatch® **SG** Pulmonary Patch
CryoGraft® Descending Thoracic Aorta
CryoArtery® Aortoiliac Artery
CryoArtery® Femoral Artery
CryoVein® Saphenous Vein
CryoVein® Femoral Vein
CryoVein® **PC** Pediatric Conduit
CryoPatch® Autologous Pericardium

Thoracic Aorta Stent Grafts Solutions

AMDS™ Hybrid Prosthesis
E-vita® **Open Neo** Hybrid Stent Graft System
E-vita® **Open Plus** Stent Graft System
NEXUS® Aortic Arch Stent Graft System
E-vita® **Thoracic 3G** Stent Graft System

Surgical Sealant

BioGlue® Surgical Adhesive

Abdominal Aorta Stent Graft Solutions

E-nside™ **TAAA** Multibranch Stent Graft System
E-tegra™ Stent Graft System
E-liac™ Stent Graft System

Peripheral Stent Graft Solutions

E-liac™ Stent Graft System
E-ventus™ Peripheral Stent Graft System

Cardiac and Vascular Ancillary Solutions

CardioGenesis® Cardiac Laser Therapy
PhotoFix® Decellularized Bovine Pericardium
CarbonAid® CO_2 Diffuser
CarbonMini® CO_2 Diffuser
E-wire Guidewire
FlowLine Bipore
E-xpand Stent Graft Balloon Catheter
FlowLine Bipore Heparin
FlowNit Bioseal
FlowWeave Bioseal

Note: All products and indications are not available/approved in all markets. Please contact your local Artivion representative for details.

ARTIVION™
Formerly CryoLife | Jotec

CAUTION ABOUT FORWARD-LOOKING STATEMENTS: Information included in this brochure may contain forward-looking statements that involve risks and uncertainties regarding future events and future results. When used in this brochure, forward-looking statements are generally accompanied by terms or phrases such as "estimate," "project," "predict," "believe," "expect," "continue," "anticipate," "target," "could," "plan," "intend," "seek," "goal," "will," "should," "may," "poised," or other words and similar expressions that convey the uncertainty of future events or outcomes and include statements about our increases in our sales associate headcount and about our beliefs that we are poised to deliver double-digit growth driven by new product launches, international expansion, regulatory approvals, and our R&D pipeline. Such forward-looking statements reflect the views of management at the time such statements are made and are subject generally to other risks and uncertainties.

Outreach Programs are conducted in accordance with applicable local and international law and regulation and Artivion's Code of Ethics and other applicable Company policies. Outreach Programs are conducted without regard to past or potential future sales.

Fred Hoiberg is a paid consultant of Artivion, Inc.

CAUTION: U.S. Federal law restricts these products to sale by or on the order of a physician. Rx only. Refer to product instructions, manuals, and package inserts for instructions, warnings, precautions, and contraindications. Devices not approved for use in all markets.

Global Headquarters

1655 Roberts Blvd., NW
Kennesaw, GA 30144 USA

Telephone: +1.888.427.9654
Domestic Fax: +770.590.3753
International Fax: +770.590.3797

artivion.com

For information on additional Artivion locations,
please visit **artivion.com/contact**

NYSE: AORT

MLENG1509.000 (2022-01)

ARTIVION™